Vascular Endothelial Growth Factor Plus Epidermal Growth Factor Receptor Dual Targeted Therapy in Metastatic Colorectal Cancer: Synergy or Antagonism?

Table 2

Comparison of adverse events of interest in the PACCE and CAIRO2 studies.

	PACCE oxaliplatin cohort [43]				CAIRO2 [47]
	(𝑁=823)				(𝑁=755)
	Ox + Bev + Pmab		Ox + Bev		Cap, Ox + Bev + Cmab	Cap, Ox + Bev
	Grade 3	Grade 4	Grade 3	Grade 4	Grade 3/4	Grade 3/4
Incidence of toxicity, %
Skin toxicity	35	1	1	0	39.1	20.8
Diarrhea	22	2	12	1	26.0	19.1
Infection	16	2	8	2	6.0	6.8
Hypertension	4	0	5	0	9.3	14.8
Hypomagnesemia	3	1	0	0	NR	NR
Neuropathy*	3	<1	7	0	7.7	10.4
Nausea/vomiting^†	13	0	6	1	6.3/6.0*	8.5/8.2*
Deep vein thrombosis	7	0	8	0	NR	NR
Pulmonary embolism	0	6	0	4	NR	NR
Venous thromboembolic events	NR	NR	NR	NR	8.2	6.8
Arterial thromboembolic events	NR	NR	NR	NR	2.2	3.3

Bev: bevacizumab; Cap: capecitabine; Cmab: cetuximab; NR: not reported; Ox: oxaliplatin; PACCE: Panitumumab Advanced Colorectal Cancer Evaluation; Pmab: panitumumab.
*Neuropathy events were reported as “sensory neuropathy” in CAIRO2.
^†The incidence of nausea and vomiting was reported together in PACCE but as separate adverse events in CAIRO2. The first number indicates the reported incidence of nausea and the second number indicates the incidence of vomiting.